Teva: Berkshire Thinks Bondholders Are 'Mullet Mullet'

Warren Buffett of Berkshire Hathaway. Source: medium.com

Teva (TEVA) has been reeling since Mylan's (MYL) generic Copaxone was approved Q4 2017. Having one's most-profitable drug go generic is never a good thing. Teva has also been hampered by the $40 billion acquisition of Allergan's (AGN) generics business. The company's credit metrics have been in a steady state of decline. It could potentially wilt under its $32 billion debt load, yet the stock is up over 80% since reporting disappointing Q3 earnings in November.

Bershire Hathaway (BRK.B), (BRK.A) even took a position in the Teva, which really assuaged Teva bulls. Below I explain what Berkshire could see in Teva.

READ FULL ARTICLE HERE